All In MedTech

Device Trial Radar · NCT05679180

Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE

Last checked: Nov 19, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 11, 2023

Primary completion

May 24, 2023

Study completion May 24, 2023

Sponsor

Lead sponsor
University Hospital, BordeauxAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).

Conditions

  • Central Serous Chorioretinopathy

Interventions

  • micropulse laserDevice

    treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. central macular thicknessTime frame: Month 3

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.